İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025 · article

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ISSN0732-183X
YÖKSİS OpenAlex Açık erişim · hybrid Üst %1
Yıl2025
Atıf20OpenAlex
Atıf21Semantic Scholar · 4 etkili
Yüzdelik%99,3
FWCI13,191,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıJournal of Clinical Oncology
  • Katalog eşleşmesi (ISSN)Journal of Clinical Oncology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

PURPOSE Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. We report results, to our knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve (TN) patients and patients with relapsed/refractory (R/R) disease. PATIENTS AND METHODS Patients (N = 662) were randomly assigned 1:1 to receive pirtobrutinib or ibrutinib. All patients were BTKi-naïve. Primary end points were overall response rate (ORR) by independent review committee (IRC) among all randomly assigned patients (intention to treat [ITT]) and in patients with R / R disease. RESULTS The study met its primary end points, demonstrating statistically significant noninferiority (NI) of IRC-ORR for pirtobrutinib versus ibrutinib in both the ITT (87.0% [95% CI, 82.9 to 90.4] v 78.5% [95% CI, 73.7 to 82.9]; ORR ratio = 1.11 [95% CI, 1.03 to 1.19]; two-sided P < .0001) and R/R populations (n = 437; 84.0% [95% CI, 78.5 to 88.6] v 74.8% [95% CI, 68.5 to 80.4]; ORR ratio = 1.12 [95% CI, 1.02 to 1.24]; two-sided P < .0001). In TN patients (n = 225), IRC-ORR was 92.9% (95% CI, 86.4 to 96.9) with pirtobrutinib versus 85.8% (95% CI, 78.0 to 91.7) with ibrutinib. Investigator assessed ORR results were consistent. Investigator-assessed progression-free survival (PFS) favored pirtobrutinib in the ITT (hazard ratio [HR], 0.57 [95% CI, 0.39 to 0.83]), R/R (HR, 0.73 [95% CI, 0.47 to 1.13]), and TN (HR, 0.24 [95% CI, 0.10 to 0.59]) populations. Cardiac adverse event rates of atrial fibrillation/flutter and hypertension were lower with pirtobrutinib. CONCLUSION Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

20atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

28
  1. Jennifer A Woyach 1
  2. Lugui Qiu 2
  3. Sebastian Grosicki 3
  4. Tomasz Wrobel 4
  5. Marcelo Capra 5
  6. Jaroslaw Czyz 6
  7. Shuhua Yi 7
  8. Ki-Seong Eom 8
  9. Anna Panovská 9
  10. Wojciech Jurczak 10
  11. Kamel Laribi 11
  12. Lutz Jacobasch 12
  13. Ross Baker 13
  14. Richy Agajanian 14
  15. Alejandro Berkovits 15
  16. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 16
  17. Stéphane Lepretre 17
  18. Catherine C Coombs 18
  19. Paula Cramer 19
  20. Katharine Lewis 20
  21. Marisa Hill 21
  22. Katherine Bao 22
  23. Yuanyuan Bian 23
  24. Silvia Ramalho De Batista Ribeiro 24
  25. Naleen Raj Bhandari 25
  26. Amy S Ruppert 26
  27. Ching Ching Leow 27
  28. William G Wierda 28